341 related articles for article (PubMed ID: 30972617)
21. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
Zeng Y; Duan X; Xu J; Ni X
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD008235. PubMed ID: 21735426
[TBL] [Abstract][Full Text] [Related]
22. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B
Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876
[TBL] [Abstract][Full Text] [Related]
23. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
24. Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series.
Vianello F; D'Amore F; Lombardi AM; Caputo I; Friziero A; Da Dalt G
Blood Coagul Fibrinolysis; 2019 Sep; 30(6):295-299. PubMed ID: 31259778
[TBL] [Abstract][Full Text] [Related]
25. Thrombopoietin receptor agonists: ten years later.
Ghanima W; Cooper N; Rodeghiero F; Godeau B; Bussel JB
Haematologica; 2019 Jun; 104(6):1112-1123. PubMed ID: 31073079
[TBL] [Abstract][Full Text] [Related]
26. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
28. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
Piccin A; Amaddii G; Natolino F; Billio A; Cortelazzo S
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912
[No Abstract] [Full Text] [Related]
29. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
Kowalczyk M; Rubinstein PG; Aboulafia DM
J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
[TBL] [Abstract][Full Text] [Related]
30. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
31. Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Rodeghiero F; Pecci A; Balduini CL
J Thromb Haemost; 2018 Sep; 16(9):1700-1710. PubMed ID: 29956472
[TBL] [Abstract][Full Text] [Related]
32. Two new drugs for chronic ITP.
Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
[TBL] [Abstract][Full Text] [Related]
33. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
34. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
[No Abstract] [Full Text] [Related]
35. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
[No Abstract] [Full Text] [Related]
36. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
[TBL] [Abstract][Full Text] [Related]
37. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
[TBL] [Abstract][Full Text] [Related]
38. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
Vibor M; Rogulj IM; Ostojic SK
Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.
Lusa A; Carlson A
Lupus; 2018 Sep; 27(10):1723-1728. PubMed ID: 29673280
[TBL] [Abstract][Full Text] [Related]
40. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
Iino M; Sakamoto Y; Sato T
Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
